HK inno.N signs deal with Eurofarma for K-CAB tablets
![HK inno.N's K-CAB tablets, which treat gastroesophageal reflux disease [HK INNO.N]](https://koreajoongangdaily.joins.com/data/photo/2023/01/27/bbfe934a-50a3-49da-9692-ff64fc81d751.jpg)
HK inno.N's K-CAB tablets, which treat gastroesophageal reflux disease [HK INNO.N]
HK inno.N inked a technology transfer deal with Brazil-based Eurofarma for its K-CAB tablets, a gastroesophageal reflux disease treatment.
Under the 10-year deal, Eurofarma will have the exclusive rights to develop and sell K-CAB in Brazil. HK inno.N will transfer its technology of manufacturing the treatment to the Brazilian company.
The size of the deal has not been declared. HK inno.N has received an undisclosed upfront payment and will get milestones and royalties based on the treatment sales.
Brazil's gastroesophageal reflux treatment market was valued at some 800 billion won ($647 million) in 2020, the largest in Latin America and the sixth largest in the world. Eurofarma is the third largest pharmaceutical company in the Latin America region.
"We aim to export K-CAB tablets to a total of 100 countries by the end of 2028," said Kwak Dal-won, CEO of HK inno.N.
Brazil is the 35th foreign country to have the treatment. HK inno.N has been awaiting approvals from a total of 27 countries, including Mexico.
K-CAB tablets generated 125.2 billion won in sales alone last year.
BY SARAH CHEA [chea.sarah@joongang.co.kr]
with the Korea JoongAng Daily
To write comments, please log in to one of the accounts.
Standards Board Policy (0/250자)